BERKELEY HEIGHTS, N.J., Oct. 31, 2013 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (“Cyclacel” or the “Company”), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 2013 Therapeutic Area Partnerships (TAP) Conference by Elsevier Business Intelligence (formerly Windhover) being held on November 18-20, 2013 at The Hyatt Regency, Boston, MA. Spiro Rombotis, President and Chief Executive Officer, will provide at 10:40 am Tuesday, November 19 an overview of the Company’s sapacitabine oral capsules investigational drug and its progress in target indications.
Help employers find you! Check out all the jobs and post your resume.
